| Neurofilament Light Chain (NfL) | |
|---|---|
| Gene | NEFL (8p21.2) |
| UniProt | P07196 |
| PDB | 3TNU |
| Mol. Weight | 68.5 kDa |
| Localization | Axonal cytoskeleton; released into CSF/blood upon injury |
| Family | Type IV intermediate filament protein |
| Filament Partners | NfM (NEFM), NfH (NEFH), α-internexin |
| Diseases (biomarker) | AD, ALS, MS, HD, FTD, PD |
| Diseases (mutations) | CMT1F/CMT2E |
Neurofilament Light Chain (Nfl) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurofilament light chain (NfL) is a 68.5 kDa type IV intermediate filament protein encoded by the NEFL gene on chromosome 8p21.2. [It is the smallest and most abundant subunit of neurofilaments — the major structural components of the axonal cytoskeleton in [neurons[/entities/neurons, particularly in large-caliber myelinated axons. [NfL[/entities/neurofilament-light has emerged as the most widely validated fluid [biomarker] of neuroaxonal damage across virtually all neurological diseases, measurable in both cerebrospinal fluid (CSF) and blood ([Khalil et al., 2018]https://doi.org/10.1038/s41582-018-0058-z)). Its clinical significance was cemented when the FDA's 2023 accelerated approval of tofersen for SOD1-[ALS[/diseases/als relied on plasma [NfL[/entities/neurofilament-light reduction as a surrogate endpoint — the first time a blood biomarker served this role in neurology (Quanterix, 2023).
The NEFL gene spans approximately 6.3 kb on chromosome 8p21.2 and contains 4 exons. Mutations in NEFL cause [Charcot-Marie-Tooth Disease[/diseases/charcot-marie-tooth-disease types 1F (demyelinating) and 2E (axonal), demonstrating the protein's critical role in axonal integrity (OMIM: 162280).
[NfL[/entities/neurofilament-light (543 amino acids, 68.5 kDa) shares the tripartite domain organization common to all intermediate filament proteins:
| Domain | Residues | Function |
|---|---|---|
| Head domain | 1–93 | Globular N-terminal region; initiates filament assembly; contains phosphorylation sites that regulate polymerization |
| Rod domain | 94–397 | Central α-helical coiled-coil domain (310 aa); mediates dimerization through heptad repeats; subdivided into coils 1A, 1B, 2A, and 2B connected by linkers |
| Tail domain | 398–543 | C-terminal domain; projects outward from filament backbone; mediates interactions with other cytoskeletal components and organelles |
NfL assembles into ~10 nm intermediate filaments through a hierarchical process:
NfL is the obligate subunit — it must be present for neurofilament assembly. It co-polymerizes with neurofilament medium chain (NfM, 145 kDa) and neurofilament heavy chain (NfH, 200 kDa) in varying stoichiometries, and also with α-internexin in the central nervous system. The ratio of NfL:NfM:NfH is approximately 7:3:2 in mature peripheral nerves.
Neurofilaments are the most abundant cytoskeletal components in large myelinated axons, determining axonal diameter — a key factor in conduction velocity. NfL-null mice show reduced axonal caliber (by ~50%), slower nerve conduction, and progressive motor dysfunction (Zhu et al., 1997). The NfM and NfH tail domains project laterally from the filament backbone, acting as spacers that regulate inter-filament distance and thus axonal diameter.
Neurofilaments move by slow axonal transport (0.5–3 mm/day) in a "stop-and-go" pattern, spending most of their time paused. NfL phosphorylation by protein kinases ([CDK5[/entities/cdk5, [GSK-3β[/entities/gsk3-beta regulates transport dynamics. Phosphorylation of the NfL head domain promotes filament disassembly and transport, while NfH tail phosphorylation promotes pausing and accumulation in axons.
Emerging evidence suggests NfL plays roles beyond structural support, including regulation of neurotransmitter receptor localization at synapses and modulation of calcium signaling through interactions with mitochondria and the endoplasmic reticulum.
When [neurons[/entities/neurons are damaged — through [neuroinflammation[/mechanisms/neuroinflammation, [excitotoxicity[/entities/excitotoxicity, [protein aggregation[/mechanisms/protein-aggregation, or mechanical injury — neurofilaments are released from disintegrating axons into the interstitial fluid, CSF, and eventually blood. NfL is the most abundant and soluble neurofilament subunit, making it the most readily detectable in body fluids.
| Platform | Sample | Sensitivity | Throughput | Clinical Use |
|---|---|---|---|---|
| Simoa (Quanterix) | Plasma/serum | Sub-pg/mL (single molecule counting) | High | Primary blood-based platform; FDA-cleared LDT |
| Ella (Bio-Techne) | Plasma/serum | Low pg/mL (microfluidic ELISA) | Medium | Alternative blood platform |
| Lumipulse (Fujirebio) | CSF | pg/mL | High | IVD-certified for CSF |
| Standard ELISA | CSF | pg/mL | Low | Legacy platform; insufficient for blood |
The Simoa (Single Molecule Array) platform, developed by Quanterix, revolutionized NfL measurement by achieving the ultrasensitivity needed to detect the low concentrations present in blood (typically 5–35 pg/mL in healthy adults), approximately 40-fold lower than CSF levels.
Plasma NfL levels are elevated in [Alzheimer's disease[/diseases/alzheimers, correlating with disease stage, rate of cognitive decline, and cortical thinning on MRI. NfL rises during the presymptomatic phase, years before clinical onset, and tracks with neurodegeneration independently of [Amyloid-Beta[/proteins/Amyloid-Beta pathology. In the [DIAN] ([Dominantly Inherited Alzheimer Network[/entities/dian-study cohort, plasma NfL diverges from normal ~16 years before expected symptom onset (Preische et al., 2019).
NfL levels are highest in [ALS[/diseases/als among all neurodegenerative diseases (often >100 pg/mL in plasma), reflecting the rapid and extensive [motor neuron[/cell-types/motor-neurons degeneration. Serum NfL distinguishes ALS from clinical mimics with high sensitivity and specificity, correlates with disease progression rate, and predicts survival (Verde et al., 2019). The FDA's 2023 approval of tofersen for SOD1-ALS was based on plasma NfL reduction (40–50% over 6 months) as a reasonably likely surrogate for clinical benefit.
In [multiple sclerosis[/diseases/multiple-sclerosis, NfL serves as a biomarker of active neuroaxonal damage, reflecting both acute relapse-associated injury and ongoing subclinical neurodegeneration. Serum NfL levels correlate with gadolinium-enhancing lesions on MRI, brain atrophy rate, and disability progression. NfL is increasingly used to monitor treatment response — effective disease-modifying therapies reduce NfL levels toward normal.
Plasma NfL is elevated in [FTD[/diseases/ftd and differentiates FTD from psychiatric disorders with high accuracy. In genetic FTD (GRN, [C9orf72[/genes/c9orf72, [MAPT[/genes/mapt mutations), NfL rises ~2–5 years before symptom onset and tracks with the rate of frontal and temporal lobe atrophy.
In [Huntington's disease[/mechanisms/huntington-pathway, plasma NfL is elevated even in premanifest mutation carriers and correlates with CAG repeat length, striatal atrophy, and proximity to clinical onset. NfL was a key pharmacodynamic biomarker in the tominersen antisense oligonucleotide trial.
NfL levels in [Parkinson's disease[/diseases/parkinsons are only mildly elevated compared to controls, limiting diagnostic utility. However, NfL helps differentiate PD from atypical parkinsonian disorders ([PSP[/diseases/psp, [MSA[/diseases/msa, [CBD[/diseases/corticobasal-degeneration, where levels are substantially higher.
Serum NfL rises acutely after [traumatic brain injury[/diseases/traumatic-brain-injury and [CTE[/mechanisms/cte-related concussions, with levels proportional to injury severity. The delayed peak (days to weeks post-injury) reflects the time course of secondary axonal degeneration.
NfL is not disease-specific — it is a universal marker of neuroaxonal damage. Several factors affect baseline levels and must be considered in clinical interpretation:
Distinct from its role as a biomarker, mutations in the NEFL gene directly cause [Charcot-Marie-Tooth Disease[/diseases/charcot-marie-tooth-disease:
Mouse models expressing CMT-associated NfL mutations develop neurofilament accumulations in neuronal cell bodies, progressive axonal degeneration, and motor impairment, recapitulating human disease.
NfL has become a standard pharmacodynamic [biomarker] in neurology clinical trials:
As of 2024–2025, 94% of IND (Investigational New Drug) programs evaluating NfL propose it as a pharmacodynamic biomarker, 52% for patient stratification, and 8% for patient selection (Thakur et al., 2025).
[Proteins Index[/proteins
[Biomarkers]
[Neurodegeneration[/neurodegeneration-research
[blood-brain barrier[/entities/blood-brain-barrier
The study of Neurofilament Light Chain (Nfl) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.